BIANCHI, FRANCESCA
BIANCHI, FRANCESCA
Dipartimento di Scienze Biomediche per la Salute
Activation of NK cell cytotoxicity by aerosolized CpG-ODN/poly(I:C) against lung melanoma metastases is mediated by alveolar macrophages
2017 M. Sommariva, V. Le Noci, C. Storti, F. Bianchi, E. Tagliabue, A. Balsari, L. Sfondrini
Aerosol 1,25-dihydroxyvitamin D3 supplementation: A strategy to boost anti-tumor innate immune activity
2021 F. Bianchi, M. Sommariva, V. Le Noci, S. Camelliti, N. Gagliano, M. Giussani, A. Balsari, E. Tagliabue, L. Sfondrini
Antibiotics treatment impairs the growth of murine triple negative mammary tumors by altering the tumor associated microbiota
2021 V.M. LE NOCI, E. Ottaviano, G. Bernardo, C. Camisaschi, T. Triulzi, S.D. Guglielmetti, M. Di Modica, P.M. Sartori, F. Bianchi, S.L. Indino, M. Sommariva, E. Borghi, E. Tagliabue, L. Sfondrini
Ascites regression and survival increase in mice bearing advanced-stage human ovarian carcinomas and repeatedly treated intraperitoneally with CpG-ODN
2010 M. De Cesare, L. Sfondrini, M. Campiglio, M. Sommariva, F. Bianchi, P. Perego, N. van Rooijen, R. Supino, C. Rumio, F. Zunino, G. Pratesi, E. Tagliabue, A. Balsari
CDCP1 is a novel marker of the most aggressive human triple-negative breast cancers
2016 F. Turdo, F. Bianchi, P. Gasparini, M. Sandri, M. Sasso, L. De Cecco, L. Forte, P. Casalini, P. Aiello, L. Sfondrini, R. Agresti, M.L. Carcangiu, I. Plantamura, G. Sozzi, E. Tagliabue, M. Campiglio
Circulating biomarkers in advanced colorectal cancer patients randomly assigned to three bevacizumab-based regimens
2014 A. Martinetti, R. Miceli, E. Sottotetti, M. Di Bartolomeo, F. de Braud, A. Gevorgyan, K.F. Dotti, E. Bajetta, M. Campiglio, F. Bianchi, G. Bregni, F. Pietrantonio
COPZ1 depletion in thyroid tumor cells triggers type I IFN response and immunogenic cell death
2020 T. Di Marco, F. Bianchi, L. Sfondrini, K. Todoerti, I. Bongarzone, E.M. Maffioli, G. Tedeschi, M. Mazzoni, S. Pagliardini, S. Pellegrini, A. Neri, M.C. Anania, A. Greco
Decoding immune heterogeneity of triple negative breast cancer and its association with systemic inflammation
2019 S. Romero-Cordoba, E. Meneghini, M. Sant, M.V. Iorio, L. Sfondrini, B. Paolini, R. Agresti, E. Tagliabue, F. Bianchi
Deep Into Breast Cancer Heterogeneity to Increase Immunotherapeutic Effectiveness
2020 S. Romero-Cordoba, E. Tagliabue, T. Triulzi, F. Bianchi
Effect of adjuvant trastuzumab treatment in conventional clinical setting : an observational retrospective multicenter Italian study
2013 M. Campiglio, R. Bufalino, M. Sasso, E. Ferri, P. Casalini, V. Adamo, A. Fabi, R. Aiello, F. Riccardi, E. Valle, V. Scotti, G. Tabaro, D. Giuffrida, E. Tarenzi, A. Bologna, G. Mustacchi, F. Bianchi, A. Balsari, S. Ménard, E. Tagliabue
Environmental and Lifestyle Cancer Risk Factors: Shaping Extracellular Vesicle OncomiRs and Paving the Path to Cancer Development
2023 V. Bollati, P. Monti, D. Biganzoli, G. Marano, C. Favero, S. Iodice, L. Ferrari, L. Dioni, F. Bianchi, A.C. Pesatori, E.M. Biganzoli
Exploiting poly(I:C) to induce cancer cell apoptosis
2017 F. Bianchi, S. Pretto, E. Tagliabue, A. Balsari, L. Sfondrini
Expression and prognostic significance of the autoimmune regulator gene in breast cancer cells
2016 F. Bianchi, M. Sommariva, L. De Cecco, T. Triulzi, S. Romero Cordoba, E. Tagliabue, L. Sfondrini, A. Balsari
Extracellular matrix features discriminate aggressive HER2-positive breast cancer patients who benefit from trastuzumab treatment
2020 I. Rybinska, M. Sandri, F. Bianchi, R. Orlandi, L. De Cecco, P. Gasparini, M. Campiglio, B. Paolini, L. Sfondrini, E. Tagliabue, T. Triulzi
Fhit expression protects against HER2-driven breast tumor development: Unraveling the molecular interconnections
2007 F. Bianchi, E. Tagliabue, S. Menard, M. Campiglio
Fhit nuclear import following EGF stimulation sustains proliferation of breast cancer cells
2015 F. Bianchi, M. Sasso, F. Turdo, G.L. Beretta, P. Casalini, C. Ghirelli, L. Sfondrini, S. Ménard, E. Tagliabue, M. Campiglio
FHIT-proteasome degradation caused by mitogenic stimulation of the EGF receptor family in cancer cells
2006 F. Bianchi, A. Magnifico, C. Olgiati, N. Zanesi, Y. Pekarsky, E. Tagliabue, C.M. Croce, S. Menard, M. Campiglio
Gut microbiota condition the therapeutic efficacy of trastuzumab in HER2-positive breast cancer
2021 M. Di Modica, G. Gargari, V. Regondi, A. Bonizzi, S. Arioli, B. Belmonte, L. De Cecco, E. Fasano, F. Bianchi, A. Bertolotti, C. Tripodo, L. Villani, F. Corsi, S. Guglielmetti, A. Balsari, T. Triulzi, E. Tagliabue
HER2 mRNA Levels, Estrogen Receptor Activity and Susceptibility to Trastuzumab in Primary Breast Cancer
2022 T. Triulzi, V. Regondi, E. Venturelli, P. Gasparini, C. Ghirelli, J. Groppelli, M. DI MODICA, F. Bianchi, L. de cecco, L. Sfondrini, E. Tagliabue
HER2 splice variants and their relevance in breast cancer
2011 M. Sasso, F. Bianchi, V. Ciravolo, E. Tagliabue, M. Campiglio